These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37382130)

  • 1. [Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial].
    Zhu Y; Wu L; Wang Y; Zhu YF; Peng Y; Fang SH; Zhang LD; Deng F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jun; 25(6):606-611. PubMed ID: 37382130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
    Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Incidence of hypogammaglobulinaemia in children with steroid-dependent/frequently relapsing nephrotic syndrome treated with rituximab and its association with severe infections].
    Zhi YZ; Cao L; Ying DJ; Dou WJ; Gu R; Zhang JJ
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):433-439. PubMed ID: 38326055
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
    Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
    Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
    Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
    Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
    Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
    World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Dose of Rituximab in Children with Steroid-Dependent / Frequently Relapsing Nephrotic Syndrome, Clinical Efficacy and Evaluation of Health-Related Quality of Life.
    Wang L; Hua R; Zhu Y; Lu Y; Gao H; Xia X; Zhang Q; Lu L; Deng F
    Iran J Kidney Dis; 2021 Mar; 1(2):109-115. PubMed ID: 33764321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.
    Hogan J; Perez A; Sellier-Leclerc AL; Vrillon I; Broux F; Nobili F; Harambat J; Bessenay L; Audard V; Faudeux C; Morin D; Pietrement C; Tellier S; Djeddi D; Eckart P; Lahoche A; Roussey-Kesler G; Ulinski T; Boyer O; Plaisier E; Cloarec S; Jolivot A; Guigonis V; Guilmin-Crepon S; Baudouin V; Dossier C; Deschênes G
    BMJ Open; 2020 Sep; 10(9):e037306. PubMed ID: 32967877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
    Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
    Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
    Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
    Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.
    Choi N; Min J; Kim JH; Kang HG; Ahn YH
    Pediatr Nephrol; 2024 Mar; 39(3):771-780. PubMed ID: 37682369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
    Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
    Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital.
    Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
    An Pediatr (Engl Ed); 2022 Feb; 96(2):83-90. PubMed ID: 35144901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.